Foghorn Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 106

Employees

  • Stock Symbol
  • FHTX

Stock Symbol

  • Share Price
  • $1.73
  • (As of Friday Closing)

Foghorn Therapeutics General Information

Description

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 99 Coolidge Avenue
  • Suite 500
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 99 Coolidge Avenue
  • Suite 500
  • Watertown, MA 02472
  • United States
+1 (617)

Foghorn Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Foghorn Therapeutics Stock Performance

As of 20-Nov-2026, Foghorn Therapeutics’s stock price is $1.73. Its current market cap is $103M with 60M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.73 $1.78 $1.66 - $7.61 $103M 60M 840K $0.10

Foghorn Therapeutics Financials Summary

As of 30-Sep-2026, Foghorn Therapeutics has a trailing 12-month revenue of $112M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 87,526 147,628 34,073 59,494
Revenue 112,129 30,909 22,602 34,155
EBITDA 4,315 (79,696) (95,400) (101,575)
Net Income 9,420 (74,283) (86,620) (98,426)
Total Assets 190,952 198,103 283,982 285,916
Total Debt 43,868 41,270 37,131 45,073
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Foghorn Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Foghorn Therapeutics‘s full profile, request access.

Request a free trial

Foghorn Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Foghorn Therapeutics‘s full profile, request access.

Request a free trial

Foghorn Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new c
Drug Discovery
Watertown, MA
106 As of 2025

Watertown, MA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Foghorn Therapeutics Competitors (10)

One of Foghorn Therapeutics’s 10 competitors is Kymera Therapeutics, a Formerly VC-backed company based in Watertown, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymera Therapeutics Formerly VC-backed Watertown, MA
Arvinas Formerly VC-backed New Haven, CT
Nurix Therapeutics Formerly VC-backed San Francisco, CA
Vividion Therapeutics Formerly VC-backed San Diego, CA
C4 Therapeutics Formerly VC-backed Watertown, MA
You’re viewing 5 of 10 competitors. Get the full list »

Foghorn Therapeutics Patents

Foghorn Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026090300-A1 Compounds and uses thereof Pending 23-Oct-2024
WO-2026090317-A1 Compounds and uses thereof Pending 23-Oct-2024
WO-2026090330-A1 Compounds and uses thereof Pending 23-Oct-2024
WO-2026090340-A1 Methods of treating metabolic disorders Pending 23-Oct-2024
WO-2026085172-A1 Combination therapy for treating hematological cancers Pending 16-Oct-2024 A61K31/5377
To view Foghorn Therapeutics’s complete patent history, request access »

Foghorn Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Foghorn Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Foghorn Therapeutics‘s full profile, request access.

Request a free trial

Foghorn Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Foghorn Therapeutics’s complete esg history, request access »

Foghorn Therapeutics FAQs

  • When was Foghorn Therapeutics founded?

    Foghorn Therapeutics was founded in 2015.

  • Where is Foghorn Therapeutics headquartered?

    Foghorn Therapeutics is headquartered in Watertown, MA.

  • What is the size of Foghorn Therapeutics?

    Foghorn Therapeutics has 106 total employees.

  • What industry is Foghorn Therapeutics in?

    Foghorn Therapeutics’s primary industry is Drug Discovery.

  • Is Foghorn Therapeutics a private or public company?

    Foghorn Therapeutics is a Public company.

  • What is Foghorn Therapeutics’s stock symbol?

    The ticker symbol for Foghorn Therapeutics is FHTX.

  • What is the current stock price of Foghorn Therapeutics?

    As of 20-Nov-2026 the stock price of Foghorn Therapeutics is $1.73.

  • What is the current market cap of Foghorn Therapeutics?

    The current market capitalization of Foghorn Therapeutics is $103M.

  • What is Foghorn Therapeutics’s current revenue?

    The trailing twelve month revenue for Foghorn Therapeutics is $112M.

  • Who are Foghorn Therapeutics’s competitors?

    Kymera Therapeutics, Arvinas, Nurix Therapeutics, Vividion Therapeutics, and C4 Therapeutics are some of the 10 competitors of Foghorn Therapeutics.

  • What is Foghorn Therapeutics’s annual earnings per share (EPS)?

    Foghorn Therapeutics’s EPS for 12 months was $0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process